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Valuing preferences for treating screen detected ductal 
carcinoma in situ
Abstract
Background :  Mammographic screening reduces breast cancer mortality but may lead to the 
overdiagnosis and overtreatment of low-risk breast cancers. Conservative management may reduce 
the potential harm of overtreatment, yet little is known about the impact upon quality of life.
Objectives :  To quantify women's preferences for managing low-risk screen detected ductal 
carcinoma in situ (DCIS), including the acceptability of active monitoring as an alternative 
treatment.
Methods : Utilities (cardinal measures of quality of life) were elicited from 172 women using 
visual analogue scales (VASs), standard gambles, and the Euro-Qol-5D-5L questionnaire for seven 
health states describing treatments for low-risk DCIS. Socio-demographics and breast cancer 
history were examined as predictors of utility.
Results : Both patients and non-patients valued active monitoring more favourably on average than 
conventional treatment. Utilities were lowest for DCIS treated with mastectomy (VAS: 0.454) or 
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breast conserving surgery (BCS) with adjuvant radiotherapy (VAS: 0.575). The utility of active 
monitoring was comparable to breast conserving surgeryBCS alone but was rated more favourably 
as progression risk was reduced from 40% to 10%. Disutility for active monitoring was likely 
driven by anxiety around progression, whereas conventional management impacted other 
dimensions of quality of life. The heterogeneity between individual preferences could not be
 explained by socio-demographic variables, suggesting that the factors influencing women's 
preferences are complex.
Conclusions : Active monitoring of low-risk DCIS is likely to be an acceptable alternative for 
reducing the impact of overdiagnosis and overtreatment in terms of quality of life. Further research 
is required to determine sub-groups more likely to opt for conservative management.
Keywords: Breast cancer; Ductal carcinoma in situ; Active monitoring; Surgery; Radiotherapy; Utility; 
Quality of life
1 Introduction
Breast cancer screening reduces breast cancer morbidity and mortality [1,2] but may also lead to the 
overdiagnosis of low-risk disease [3]. Ductal carcinoma in situ (DCIS) is a heterogeneous disease with 
variable malignant potential [4], but it is not known which patients may be safely left untreated. Standard 
treatment encompasses surgery, with or without radiotherapy, and endocrine therapy [5]. There is evidence to 
suggest that active monitoring of low-risk DCIS (defined as low or low-intermediate grade on histopathology) 
may reduce treatment-related harm from overdiagnosis [6]. Clinical trials comparing conventional treatment to 
active monitoring are underway [7–9]. However, little is known about the acceptability of active monitoring or 
how such strategies may impact upon quality of life.
The value of treating DCIS versus active monitoring is dependent on the trade-off in benefits and costs [10,11
]. For most women, this is related to the fear and sequalae of progression or recurrence versus the side-effects 
and morbidity of treatment [12]. In order tTo appraise the expected impact of each option on quality of life, 
utilities are an appropriate outcome measure [13]. Utilities are cardinal measures of quality of life [14], 
representing the strength of an individuals’ preference for a health state or treatment. They are measured on a 
scale from 0 to 1, equivalent to being dead and in perfect health, respectively, and are used to measure benefit 
(quality-adjusted -life-years) in economic evaluations informing healthcare decisions [15].
Issues surrounding DCIS management arise from the uncertainty in disease progression. DCIS is not life-
threatening but is a risk factor for developing invasive breast cancer [16]. Whilst surgery and radiotherapy may 
reduce the risk of invasive cancer and need for more invasive treatment if it does not progress, it is unlikely to 
have significant benefit upon survival [17]. Conversely, many women are exposed to the morbidity and costs 
of the initial treatment to reduce the risk of recurrence.




Utilities were elicited for seven hypothetical health states describing treatments for low-risk DCIS: (A) breast 
conserving surgery (BCS) alone, (B) BCS with radiotherapy, (C) mastectomy +/- reconstruction, (D) active 
monitoring with 40% risk of progression in 10 years, (E) active monitoring with 20% risk of progression in 10 
years, (F) active monitoring with 10% risk of progression in 10 years and (G) treatment for progressed DCIS.
Health states were defined in a series of vignettes representing the treatments and clinical consequences 
associated with DCIS diagnosed at screening ( ). Descriptions were developed from clinical 
guidelines, systematic literature review [18], and consultation with clinicians. The risk of overdiagnosis and 
cancer progression wasere explicitly included using three hypothetical estimates of breast cancer progression 
from meta-analyses [19] and recurrence rates after treatment from clinical trials [20]. Progressed DCIS was 
included to determine the magnitude of effect of an adverse outcome following surveillance. Endocrine 
treatment was optional for those with hormone positive disease.
Health states were unlabelled and used mixed framing to reduce bias in the presentation of potential benefits 
and risks [21]. Vignettes were piloted on patients to check content validity.
2.2 Eligibility
Utilities were obtained from women in Melbourne, Australia, between April and September 2018. Eligible 
women had to be aged over 30 years (breast cancer is uncommon below this threshold) and have basic oral and 
written English to complete the tasks. Both patient (DCIS/early invasive breast cancer) and non-patient 
(women without breast cancer) preferences were elicited, so values between groups with different disease 
knowledge could be explored. Women with advanced breast cancer or those undergoing active management 
(except for tamoxifen or aromatase inhibitors) were excluded.
2.3 Recruitment
Women were invited to participate by email invitation through the Lifepool cohort and Breast Cancer Network 
Australia's Review & Survey group. The two groups consist of registry of Australian members interested in 
participating in breast cancer research. Women were asked to contact the researchers if interested and were 
invited for interview. Additional women contacted the researchers through participant snowball sampling. All 
those who replied and met eligibility were included for sampling.
Individual interviews were undertaken at the University of Melbourne and local community facilities in 
Victoria. Two interviews were conducted via telecommunication to accommodate participants’ disabilities. No 
financial incentive was provided. The study was approved by the Health Sciences Ethics Sub-Ccommittee at 
the University of Melbourne (ID: 1750252).
2.4 Interviews
Supplementary file
Women were interviewed face-to-face by a single interviewer (HB). The interview used an adaptation of the 
format described by Hayman et al. [22] and consisted of four parts: a rating scale, EuroQol-5 dimensions (EQ-
5D)-5L, standard gamble and socio-demographic questionnaire ( ).
Participants were asked to read, in random order, seven hypothetical health states and rank them from least to 
most desirable on a 20 cm visual analogue scale, anchored from worst (0) to best (100) imaginable health. 
They were also asked to place being dead on the same scale so that health states could be adjusted to the dead-
perfect health scale [15]. Second, participants were asked to rate the health states in terms of the five EQ-5D-
5L [23] domains of quality of life (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression). Each dimension was divided into five hierarchical levels of severity, and scores were 
converted into utilities using general population tariffs [24].
For the standard gamble, participants were asked to choose between two alternatives: (i) a gamble between 
varying probabilities of perfect health and being dead or (ii) the health state being evaluated. The probabilities 
of the gamble were varied (ping-pong technique) until the participant was indifferent between the two 
alternatives, corresponding to the utility for the health state [25]. For comparability, participants were asked to 
consider that all states lasted 10-years in line with clinical trials of active monitoring [7]. Visual aids consisting 
of a chance board and probability wheel were used to aid comprehension [26]. Demographics were collected 
to enable subgroup and regression analyses.
2.5 Statistical analysis
Data analysis was carried out using STATA 14.0. The methods described by Hayman [27] were used to 
estimate a proxy sample size: the reported standard deviation of patient standard gambleSG utilities is 0.2, thus 
requiring a minimum of 100 women for mean utilities to be estimated at a 95% confidence level of 0.04, with 
a power of 90%.
Differences in characteristics between patients and non-patients were analysed using t-tests and Chi-squared 
tests. Non-parametric tests were used to analyse utilities due to the non-normal distribution of the data [28]. 
Mann–-Whitney U test was used to determine whether utilities differed between patient and non-patients. 
Correlation between methods was assessed using the Spearman's correlation coefficient and linear regression 
to determine if demographic variables were predictors of utility [29].
3 Results
3.1 Sample characteristics
A total of 929 women were invited and a further 36 women identified through snowball sampling. Out of 254 




All 94 patients and 78 non-patients successfully completed the interview in full. Patients took longer on 
average (56 versus 45 min, P < 0.001), but there was no significant difference in questionnaire difficulty 
reported (P  =  0.296). Socio-demographic characteristics were similar between the two groups ( Table 1 ), 
although non-patients tended to have a higher risk threshold below which they were uncomfortable to consider 
active monitoring, reported less worry and were more likely to consider active monitoring than patients.
A flow chart of patient recruitment and participation in the main study. BCNA: Breast Cancer Network Australia.
alt-text: Table 1
Table 1
A comparison of participant demographics.
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Demographic % of Patients (n = 94) % of Non-patients (n = 78) P value
Age in years: Mean (SD) 66.2 (6.7) 58.7 (11.9) **0.007
Education level:   
0.094
 Secondary school 14 (15) 7 (9)
 Certificate or diploma 23 (25) 16 (21)
 Undergraduate degree 19 (20) 29 (37)
 Postgraduate degree 38 (40) 26 (33)
Socio-economic income:   
0.356
 Low 12 (13) 6 (8)
 Middle 25 (27) 16 (21)
 High 44 (46) 47 (60)
 Prefer not to say 13 (14) 9 (11)
Relationship status:   
0.432
 Single 9 (10) 13 (17)
 Married 67 (70) 52 (67)
 Separated or divorced 10 (11) 6 (7)
 Widowed 8 (9) 5 (6)
 Prefer not to say 0 (0) 2 (3)
Current employment status:   
**0.032
 Full or part time 40 (43) 42 (54)
 Unemployed 2 (2) 0 (0)
 Retired 48 (51) 28 (36)
 Carer, volunteer or other 4 (4) 8 (10)
Ethnicity:   
0.286
 Australian 69 (73) 61 (78)
 New Zealand/Torres Strait Islander 4 (4) 4 (5)
 European 11 (12) 6 (8)
 Asian 3 (3) 5 (6)
 American 7 (8) 0 (0)
 Middle Eastern 0 (0) 2 (3)
3.2 Utilities
Mean and median utilities are presented in  Table 2 . Utilities are scaled from 0 to 1, whereby values closer to 1 
are indicative of a stronger preference for the health state. Overall, both patients and non-patients had the 
strongest preference for active monitoring followed by BCS, BCS with radiotherapy, mastectomy and lastly 
treatment for progression. The only exception was the VAS where BCS alone was rated more favourably by 
patients (0.61, SD 0.19). As expected, mean utilities for active monitoring increased as the risk of disease 
Attended breast screening 76 (81) 59 (76) 0.408
Undergone a breast biopsy 94 (100) 15 (19) ***0.000
Breast cancer diagnosis:   
N/A DCIS 33 (35) –
 Invasive breast cancer 61 (65) –
Treatment received:**   
N/A
 Breast conserving surgery 65 (69) –
 Mastectomy 39 (41) –
 Adjuvant radiotherapy 54 (57) –
 Endocrine therapy 56 (60) –
 Chemotherapy 36 (38) –
 Sentinel lymph node 56 (60) –
Worried about breast cancer:   
**0.015
 Not at all 23 (24) 32 (41)
 A little 49 (52) 35 (45)
 Some of the time 15 (16) 10 (13)
 A lot or all the time 7 (8) 1 (1)
Difficulty of questionnaire   
0.296
 Very easy or easy 44 (37) 35 (45)
 Neither easy nor difficult 19 (20) 12 (15)
 Difficult or very difficult 31 (33) 31 (40)
Would consider active monitoring? 57 (61) 76 (97) ***0.000
Mean % risk threshold for monitoring (SD) 84.0 (0.22) 72.0 (0.16) ***0.000
DCIS: ductal carcinoma in situ .
*Totals add up to greater than 100% as some patients received multiple treatments.
progression decreased from 40% to 10%. Utilities for most health states describing DCIS were close to perfect 
health, as indicted by the upward skew, but more invasive treatments were associated with worse average 
quality of life (mastectomy: 0.454, BCS with radiotherapy: 0.575).
alt-text: Table 2
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The EQ-5D-5L demonstrated the most consistent ranking of health states.  Fig. 2 reports the overall percentage 
of women reporting any perceived impairment in each EQ-5D dimension of quality of life. Utilities for active 
monitoring were primarily driven by anxiety/depression. In contrast, conventional treatments were perceived 
to impact upon other dimensions of health such as pain, self-care and usual activities. Consequently, utilities 











































































Total percentage of women reporting any level of impairment in each of the EQ-5D-5L dimensions of quality of life for the seven 
health states. BCS: breast conserving surgery; Rtx: radiotherapy; Mastec: mastectomy; AM: active monitoring; Progressed: 
progressed DCIS; Dep: depression; DCIS: ductal carcinoma in situ;  EQ-5D: EuroQol-5 dimensions.
Patients utilities were higher for conventional treatment using standard gambles (P = 0.005) and lower for 
active monitoring using VAS (P < 0.001), but there were no significant differences between the two groups for 
any health states using the EQ-5D-5L. Pairwise analysis demonstrated strong positive correlation between 
utilities for active monitoring (0.93, P  <  0.001) but weak positive associations between monitoring and 
intensive management (0.25, P = 0.016), i.e. women with a preference toward monitoring tended to report 
lower utilities for a mastectomy and vice versa.
Regression demonstrated that socio-demographics accounted for <5% of the variability in utilities. 
Employment and financial status had a weak positive effect on mastectomy (P = 0.068). Having breast cancer 
or a lower baseline threshold for recurrence risk was associated with a lower utility for active monitoring 
(P < 0.001).
3.3 Quality appraisal
Although there are no quality checklists for utilities, it is important to assess whether the values are valid [30]. 
The utilities demonstrated good feasibility as reflected by the lack of missing data, high completion rate and 
consistency between methods. Descriptive validity was confirmed through extensive piloting, and the three 
methods demonstrated good convergent validity and consistency in ranking across the seven health states. 
Test-–retest reliability among women participating in the pilot and main study were within expected levels of 
agreement [31] and few (6%) rated the tasks as ‘very difficult’ on a Likert scale.
4 Discussion
4.1 Principal findings
The results suggest that most women would find active monitoring an acceptable alternative to surgery for 
reducing the impact of overdiagnosis, if shown to be safe in clinical trials. Both patients and non-patients 
valued monitoring more favourably than surgery and radiotherapy on average. There was some individual 
heterogeneity suggesting that de-escalation may not be preferred by everyone, but regression suggests these 
are likely to be women with prior history of cancer or fear of progression.
The acceptability of active monitoring was highly dependent on risk of progression and perceived anxiety. 
Although on average, a 10% risk of progression in 10 years was an acceptable trade-off, some women were 
willing to accept the risk of possible side-effects from surgery or radiotherapy to reduce the risk of local 
recurrence. It is hard to predict the risk in an individual patient, and therefore, treatment is given in case it is 
beneficial [32]. This study shows that if the risk of progression is low, most women will choose observation; 
however, if the risk is high, that number is substantially reduced. Ultimately, the acceptability of active 
monitoring is dependent on defining these risks in clinical trials and communicating outcomes to patients.
There was considerable interpatient variation that could not be explained by the socio-demographic factors 
examined. Attitudes toward risk threshold [33], fear of recurrence [34] and disease knowledge vary widely [35
] and support the hypothesis that the factors influencing preferences are complex. Little is known about 
attitudes toward active monitoring and further research to identify women who are likely to benefit from 
conservative management is necessary. Gaining understanding of the risk of invasive progression will provide 
comfort for both patients and providers.
Overall, utilities were lower than in other studies, which have focused on the benefits of adjuvant radiotherapy 
[22,27] or valued in situ and invasive treatment concurrently [36]. In our study, women were provided with 
health states explicit in detailing the benefits and harms of active treatment, including the chance of 
overdiagnosis, which may explain the lower utilities observed. Women may express a higher utility to 
treatment where they believe that the treatment (and associated side-effects) are necessary or they believe they 
are lucky that the cancer has been found early and treated. Providing a more balanced assessment of the 
benefits and risk of treatment may better reflect the utility of treatment. Similarly, our methods are more likely 
to represent actual preferences than those elicited in clinical trials where women may not be able to trade-off 
the benefits and risks in surgical arms.
There are no published utilities for active monitoring in breast cancer, but the results are comparable to those 
elicited in prostate [37] and cervical cancer screening [38]. Active monitoring has been successfully 
implemented for other low risk cancers [39]. The utilities derived in this study show theoretical acceptability 
of DCIS surveillance and is encouraging information for clinicians looking to reduce the harms of 
overdiagnosis in the screening population.
4.2 Strengths and limitations
To the best of our knowledge, this is the first empirical study to value the quality of life associated with active 
monitoring for breast cancer. This is especially significant because it provides real-world data to suggest the 
acceptability of conservative approaches towards breast cancer treatment. Many women may find active 
monitoring a sensible alternative to surgery in terms of quality of life, which is likely to have significant 
implications for future health policy.
The methods used to elicit utilities were justified through rigorous systematic review. Health states were 
extensively piloted on clinical experts, academics and patients and explicitly included overdiagnosis, providing 
balanced information of the potential benefits and harms during the valuation process. This balance is 
important in addressing the limitations identified in a review of breast screening health states [18]. The 
instruments demonstrated convergent validity, but the VAS and EQ-5D are not truly ‘choice-based’ and may be 
constrained in conveying women's preferences towards hypothetical treatment.
There are limitations to any empirical research. The women recruited via cancer registries were likely more 
motivated and educated about breast cancer treatment. This study was unique in ascertaining the potential 
implications of de-escalating treatment from both a patient and population perspective but only included the 
views of women aged above over 30 years. Whether such preferences are transferable to the wider population 
may also depend on social normalities and perception of risk, particularly among younger women.
4.3 Future research and policy implications
Breast cancer treatment is moving towards a personalised, risk-based approach [40]. Whilst clinical trials may 
provide much needed clinical data on the value of de-escalating treatment, the potential policy implications of 
adopting such approaches is unknown. More research is necessary to investigate the potential oncologic 
outcomes of balancing treatment with monitoring and what a surveillance protocol might look like beforeprior 
to offering it to patients. This research provides much needed data to inform the issues highlighted around the 
treatment of women likely subject to overdiagnosis and can be used to inform economic evaluations exploring 
personalised approaches to breast cancer screening and treatment.
5 Conclusion
Active monitoring for low-risk DCIS is an acceptable choice for most women. The findings suggest that 
improved quality of life through conservative management is as important to some women as reducing local 
recurrence during the trade-offs in the treatment decision. The magnitude of the utilities suggest that active 
monitoring may be as cost-effective as breast conservative surgery, but further assessment in an economic 
evaluation and clinical trial is required to validate this.
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Highlights
• This is the first study to value the QoL of active monitoring for breast cancer.
• Screen detected ductal carcinoma in situ (DCIS) may be subject to overdiagnosis and thus overtreatment.
• Women with low-risk DCIS would prefer less invasive treatment in terms of QoL.
• Active monitoring is valued an acceptable alternative to surgery and radiotherapy.
• More research is needed on how to de-escalate and balance the effects of treatment.
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